KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Adding pembrolizumab to first-line chemotherapy, with or without bevacizumab, lengthened survival in advanced cervical cancer, the first improvement in the disease since bevacizumab was added seven years earlier.
Overview
Phase 3 placebo-controlled trial of 617 patients with persistent, recurrent or metastatic cervical cancer randomised to pembrolizumab or placebo with platinum-paclitaxel chemotherapy, with bevacizumab at investigator discretion.
In the PD-L1 combined positive score 1 or more population, median overall survival was not reached versus 16.3 months at the first analysis (hazard ratio 0.64) and 28.6 versus 16.5 months on update; progression-free survival was 10.4 versus 8.2 months.
- Combined positive score 1 or more: overall survival hazard ratio 0.64; updated median 28.6 vs 16.5 months.
- Median progression-free survival 10.4 vs 8.2 months.
Pembrolizumab plus chemotherapy with bevacizumab is the first-line standard for recurrent or metastatic cervical cancer with PD-L1 expression, which covers about nine in ten patients.
- Benefit in PD-L1-negative tumours was uncertain.
- Bevacizumab use was not randomised.
Similar pages
not linked directly; found by shared links- Key paperGOG 240: bevacizumab added to chemotherapy for advanced cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperKEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma
- Key paperEMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperinnovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- TrialPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Shares Recurrent or metastatic cervical cancer, Pembrolizumab.
- Key paperKEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer
- PersonNicoletta Colombo
Shares KEYNOTE-826, Pembrolizumab.
- Key paperKEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer